Serum von Willebrand factor for early diagnosis of lung adenocarcinoma in patients with type 2 diabetes mellitus

Zhou, Yingyi; Du, Xuan; Tang, Jiali; Wang, Qiuping; Chen, Ke; Shi, Bimin

doi:10.12998/wjcc.v8.i10.1916

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VMF is upregulated by GATA3 in the LUAD vasculature [ 16 ]. Serum VWF can be employed for the early diagnosis of LUAD in patients with type 2 diabetes mellitus [ 17 ]. The imbalance between VWF secretion and ADAMTS-13 plays a critical role in the hypercoagulability state in advanced NSCLC [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Potential Prognostic Biomarkers of Lung Adenocarcinoma Based on Bioinformatic Analysis

Hou

Cheng

2021

BioMed Research International

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD), which accounts for 60% of non-small-cell lung cancers, is poorly diagnosed and has a low average 5-year survival rate (approximately 20%). It remains the leading cause of cancer-related deaths worldwide. Studies on long noncoding RNAs (lncRNAs) in LUAD-related competing endogenous RNA (ceRNA) networks are limited. We aimed to identify novel prognostic biomarkers for LUAD using bioinformatic tools and data analysis. We systemically integrated differentially expressed genes and clinically significant modules using weighted correlation network analysis. We performed a functional analysis of the collected candidate genes and explored three LUAD-related genes (VWF, PECAM1, and COL1A1) associated with the overall survival rates of patients with LUAD. Based on Cox proportional hazards analysis of candidate mRNAs and lncRNAs together with differentially expressed microRNAs, we constructed ceRNA networks, obtained 12 lncRNAs in the ceRNA networks, and revealed seven novel lncRNAs AC021016.2, AC079630.1, AC116407.1, AC125807.2, AF131215.5, LINC01936, and RHOXF1-AS1. These lncRNAs were found to be associated with overall survival rates and are suitable for the prediction of prognosis by Kaplan-Meier survival and receiver operating characteristic curve analyses. In particular, three lncRNAs—AF131215.5, AC125807.2, and LINC01936—showed an independent prognostic value of overall survival for patients with LUAD. We evaluated the diagnostic capabilities of seven lncRNAs for patients with LUAD using principal component analysis and the Gene Set Variation Analysis index. lncRNAs and crucial genes could be effectively used for distinguishing LUAD tumors from normal tissues in the Gene Expression Omnibus profile. In particular, AC021016.2 showed a significant prognostic value in the validation dataset. Our findings reveal the significance of exploring lncRNAs in cancer-related ceRNAs using bioinformatic strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential Prognostic Biomarkers of Lung Adenocarcinoma Based on Bioinformatic Analysis

Hou

Cheng

2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Multiple studies have demonstrated that elevated plasma levels of VWF are linked to a poorer prognosis in patients with liver cancer, breast cancer, and NSCLC [ 66 , 67 ]. Additionally, the level of VWF can serve as a biomarker for the early diagnosis of liver cancer and lung adenocarcinoma [ 68 , 69 ]. Our study showed that increased levels of FGB, FGG, and VWF proteins in plasma exosomes from NSCLC patients suggest their potential as noninvasive biomarkers for NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer

Luo,

Que,

et al. 2023

Biol Proced Online

View full text Add to dashboard Cite

Background Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths worldwide, primarily due to its propensity for metastasis. Patients diagnosed with localized primary cancer have higher survival rates than those with metastasis. Thus, it is imperative to discover biomarkers for the early detection of NSCLC and the timely prediction of tumor metastasis to improve patient outcomes. Methods Here, we utilized an integrated approach to isolate and characterize plasma exosomes from NSCLC patients as well as healthy individuals. We then conducted proteomics analysis and parallel reaction monitoring to identify and validate the top-ranked proteins of plasma exosomes. Results Our study revealed that the proteome in exosomes from NSCLC patients with metastasis was distinctly different from that from healthy individuals. The former had larger diameters and lower concentrations of exosomes than the latter. Furthermore, among the 1220 identified exosomal proteins, we identified two distinct panels of biomarkers. The first panel of biomarkers (FGB, FGG, and VWF) showed potential for early NSCLC diagnosis and demonstrated a direct correlation with the survival duration of NSCLC patients. The second panel of biomarkers (CFHR5, C9, and MBL2) emerged as potential biomarkers for assessing NSCLC metastasis, of which CFHR5 alone was significantly associated with the overall survival of NSCLC patients. Conclusions These findings underscore the potential of plasma exosomal biomarkers for early NSCLC diagnosis and metastasis prediction. Notably, CFHR5 stands out as a promising prognostic indicator for NSCLC patients. The clinical utility of exosomal biomarkers offers the potential to enhance the management of NSCLC.

show abstract

Serum von Willebrand factor for early diagnosis of lung adenocarcinoma in patients with type 2 diabetes mellitus

Cited by 2 publications

References 16 publications

Potential Prognostic Biomarkers of Lung Adenocarcinoma Based on Bioinformatic Analysis

Potential Prognostic Biomarkers of Lung Adenocarcinoma Based on Bioinformatic Analysis

Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer

Contact Info

Product

Resources

About